The phase 3 randomized controlled trial led by Minit Jalan Shah at Tata Memorial Centre, enrolling 422 adults with advanced head and neck squamous cell carcinoma in India, demonstrated that ultra-low-dose nivolumab plus triple metronomic chemotherapy extended median overall survival to 10.3 months versus 6.2 months with paclitaxel-carboplatin alone. Grade 3+ adverse events dropped by roughly 10 percentage points. This RCT, presented at ASCO 2026, directly confronts the reality that fewer than 3% of eligible Indian patients access PD-1 inhibitors priced at tens of thousands annually. What the STAT coverage underplays is the structural pricing architecture sustaining these disparities: originator companies maintain high-income reference pricing even as real-world evidence from multiple observational cohorts in sub-Saharan Africa and Southeast Asia shows meaningful responses at 5-10% of standard doses. A 2023 Lancet Oncology meta-analysis of 12 low-dose PD-1 studies (n>1,800, mostly single-arm) found comparable progression-free survival in resource-limited cohorts, though with noted selection bias risks absent in Shah’s RCT design. Drug pricing patterns reveal the deeper failure—list prices for nivolumab remain anchored to U.S. market tolerance rather than manufacturing costs under $500 per gram—exacerbating survival gaps where head and neck cancer ranks among top malignancies. If validated in planned head-to-head trials against U.S. standards, low-dose regimens could recalibrate global formularies, forcing reassessment of flat dosing across 12 FDA-approved PD-1/PD-L1 agents and reducing the 90%+ access deficit in low-resource settings.